SGS expands Saint-Benoît lab to boost bioanalytical capacity

SGS has expanded its Saint-Benoît laboratory near Poitiers, France, adding space and modernized capabilities for pharmaceutical bioanalysis and drug development. The upgrade is meant to support larger, more complex preclinical and clinical programs as demand grows across oncology, infectious disease and other therapeutic areas.

Why it matters: - The expansion gives SGS more room to handle growing sample volumes and more complex bioanalytical studies. - The upgraded site is aimed at helping pharmaceutical and biotechnology companies move drug development programs faster while maintaining data quality. - The added capacity matters for therapies in areas such as oncology and infectious diseases, where development programs can be highly complex.

What happened: - SGS expanded its Saint-Benoît laboratory near Poitiers, France, a site focused on pharmaceutical bioanalysis and drug development. - The project added 500 m² to the laboratory. - Renovations to existing areas brought the site’s total footprint to nearly 4,500 m² of modernized laboratory space. - The laboratory has supported preclinical and clinical programs for more than 35 years.

The details: - The Saint-Benoît laboratory supports drug development from the preclinical phase through clinical trials. - Its services include quantification of small molecules, monoclonal antibodies, biologics, ADCs and RNAs. - The site also provides pharmacokinetic and pharmacodynamic testing, immunogenicity testing, biomarker assessment and radioimmunoassay. - All activities are performed under international GCP and GLP standards. - The upgraded facility includes advanced technologies and optimized workflows. - SGS says the new setup improves operational flexibility and turnaround times. - The expansion is designed to support large-scale studies and increasingly complex programs.

Between the lines: - The investment signals SGS is betting on sustained demand for outsourced bioanalytical services as drug pipelines become more technically demanding. - Automation, digitalization and academic collaboration are becoming part of the site’s long-term strategy, not just the physical expansion. - SGS says the laboratory’s ties with the University of Poitiers help build scientific talent and technical capability.

What's next: - SGS plans to keep investing in innovation at Saint-Benoît through automation, digitalization and collaboration with academic partners. - The company expects the expanded lab to support future studies with greater speed and flexibility. - Walid Elbast, Director of the Saint-Benoît laboratory, said the expansion strengthens the site’s ability to manage larger programs and train future scientists.

The bottom line: - SGS is scaling up a key bioanalytical hub to meet rising complexity in drug development and support faster delivery of new therapies.